• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconPharmaceutical Industry

Pharmaceutical Industry

Page 89 of 100
A Starbucks cafe in Sanlitun. For the third quarter of 2015
FeaturesPharma megadeal and Starbucks earnings — 5 things to know today
By Tom Huddleston Jr. and Geoffrey SmithOctober 29, 2015
Allergan Inc.'s Botox Cosmetic As Actavis Plc Buys Drugmaker For $66 Billion
HealthWhen Viagra met Botox: Pfizer, Allergan eye mega-merger
By Geoffrey SmithOctober 29, 2015
Cholesterol lowering pill
HealthThis drug will make your flu shot less effective
By TIMEOctober 29, 2015
J. Michael Pearson, chief executive officer, Valeant Pharmaceuticals International Inc., speaks during the Bloomberg Economic Series: Canada 2015 in Toronto, Ontario Thursday May 21/2015. (Photo by Kevin Van Paassen/Bloomberg)
FinanceValeant accounting scandal: 4 critical questions that have been left unanswered
By Stephen GandelOctober 26, 2015
Why the drug price scandal won’t be enough to keep down prices
RetailWhy the drug price scandal won’t be enough to keep down prices
By Laura LorenzettiOctober 26, 2015
Imprimis Turing Drug
HealthThis company is offering a $1 alternative to Turing’s $750 drug
By Laura LorenzettiOctober 23, 2015
MSMB Capital Management CIO Martin Shkreli
HealthThis super-expensive drug is getting a $1 rival
By Benjamin SnyderOctober 23, 2015
J. Michael Pearson, chief executive officer, Valeant Pharmaceuticals International Inc., speaks during the Bloomberg Economic Series: Canada 2015 in Toronto, Ontario Thursday May 21/2015. (Photo by Kevin Van Paassen/Bloomberg)
FinanceValeant short seller on pharmacy alliance: It’s the ‘turd in the punch bowl’
By Stephen GandelOctober 22, 2015
J. Michael Pearson, Chairman of the board and Chief Executive Officer of Valeant Pharmaceuticals International Inc., waits for the start of their annual general meeting in Laval, Quebec
FinanceValeant’s accounting problems: It gets worse
By Stephen GandelOctober 22, 2015
Big pharma won’t stay silent in drug pricing debate for long
HealthBig pharma won’t stay silent in drug pricing debate for long
By Erika FryOctober 22, 2015
New Reasearch Shows That Aspirin May Cut Breast Cancer Risk
HealthThe world’s biggest clinical trial is for one of the cheapest drugs
By Claire GrodenOctober 22, 2015
J. Michael Pearson, chief executive officer, Valeant Pharmaceuticals International Inc., speaks during the Bloomberg Economic Series: Canada 2015 in Toronto, Ontario Thursday May 21/2015. (Photo by Kevin Van Paassen/Bloomberg)
FinanceForget the plunging stock price, here’s Valeant’s biggest problem
By Laura LorenzettiOctober 22, 2015
J. Michael Pearson, chief executive officer, Valeant Pharmaceuticals International Inc., speaks during the Bloomberg Economic Series: Canada 2015 in Toronto, Ontario Thursday May 21/2015. (Photo by Kevin Van Paassen/Bloomberg)
HealthShort-seller: Is Valeant the pharmaceutical Enron?
By Laura LorenzettiOctober 21, 2015
519891667
HealthDrug companies are paying huge sums to fast-track FDA approval
By Laura LorenzettiOctober 20, 2015
MSMB Capital Management CIO Martin Shkreli
LeadershipThe face of high drug prices is trolling Bernie Sanders on Twitter
By Michal AddadyOctober 19, 2015
1...
  • 87
  • 88
  • 89
  • 90
  • 91
...100
Most Popular
Economy
The Pentagon said Iran War costs $29 billion, but the real cost is closer to $200 billion—and countingplaceholder alt text
By Jacqueline MunisJune 24, 2026
Success
After forcing workers back to the office, Goldman Sachs and JPMorgan Chase are now letting their staff work remotely—but only for the World Cupplaceholder alt text
By Orianna Rosa RoyleJune 23, 2026
Retail
Amazon's record Prime Day masks a darker truth: Americans are spending more and getting lessplaceholder alt text
By Nick LichtenbergJune 24, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.